2017; Scherpereel et al., 2018). Combination treatment with pemetrexed (PMX, also known as Alimta and LY231514) and cisplatin has been the first-line chemotherapy regimen for more than a decade ...

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...

For several INNs, such as Olanzapine and Montmorillonite, a significantly prominent price reduction was also observed in second bidding. Three INNs (Losartan, Cefuroxime, and Pemetrexed) observed ...

showing Tyvyt outperformed placebo when added to treatment with Lilly’s big-selling chemotherapy Alimta (pemetrexed) and platinum drugs in patients with previously-untreated non-squamous NSCLC ...